|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MROH6 |
Gene summary for MROH6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MROH6 | Gene ID | 642475 |
| Gene name | maestro heat like repeat family member 6 | |
| Gene Alias | C8orf73 | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | A6NGR9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 642475 | MROH6 | P1T-E | Human | Esophagus | ESCC | 2.97e-02 | 1.51e-01 | 0.0875 |
| 642475 | MROH6 | P2T-E | Human | Esophagus | ESCC | 3.68e-05 | 1.26e-01 | 0.1177 |
| 642475 | MROH6 | P5T-E | Human | Esophagus | ESCC | 6.04e-03 | 7.98e-02 | 0.1327 |
| 642475 | MROH6 | P8T-E | Human | Esophagus | ESCC | 1.06e-12 | 2.75e-01 | 0.0889 |
| 642475 | MROH6 | P9T-E | Human | Esophagus | ESCC | 3.05e-07 | 1.82e-01 | 0.1131 |
| 642475 | MROH6 | P10T-E | Human | Esophagus | ESCC | 1.71e-09 | 1.21e-01 | 0.116 |
| 642475 | MROH6 | P11T-E | Human | Esophagus | ESCC | 1.13e-06 | 3.35e-01 | 0.1426 |
| 642475 | MROH6 | P12T-E | Human | Esophagus | ESCC | 8.09e-09 | 1.08e-01 | 0.1122 |
| 642475 | MROH6 | P16T-E | Human | Esophagus | ESCC | 2.21e-18 | 2.58e-01 | 0.1153 |
| 642475 | MROH6 | P21T-E | Human | Esophagus | ESCC | 6.35e-18 | 3.70e-01 | 0.1617 |
| 642475 | MROH6 | P22T-E | Human | Esophagus | ESCC | 1.55e-03 | 7.56e-02 | 0.1236 |
| 642475 | MROH6 | P23T-E | Human | Esophagus | ESCC | 1.14e-03 | 1.12e-01 | 0.108 |
| 642475 | MROH6 | P24T-E | Human | Esophagus | ESCC | 6.02e-06 | 6.81e-02 | 0.1287 |
| 642475 | MROH6 | P26T-E | Human | Esophagus | ESCC | 8.43e-12 | 1.49e-01 | 0.1276 |
| 642475 | MROH6 | P28T-E | Human | Esophagus | ESCC | 2.50e-13 | 2.10e-01 | 0.1149 |
| 642475 | MROH6 | P37T-E | Human | Esophagus | ESCC | 3.53e-03 | 9.95e-02 | 0.1371 |
| 642475 | MROH6 | P38T-E | Human | Esophagus | ESCC | 2.66e-02 | 1.47e-01 | 0.127 |
| 642475 | MROH6 | P42T-E | Human | Esophagus | ESCC | 2.93e-03 | 1.04e-01 | 0.1175 |
| 642475 | MROH6 | P47T-E | Human | Esophagus | ESCC | 1.77e-03 | 1.52e-01 | 0.1067 |
| 642475 | MROH6 | P49T-E | Human | Esophagus | ESCC | 4.64e-06 | 3.00e-01 | 0.1768 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MROH6 | SNV | Missense_Mutation | rs748151785 | c.1063N>A | p.Asp355Asn | p.D355N | A6NGR9 | protein_coding | tolerated(0.64) | probably_damaging(0.998) | TCGA-BH-A18F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| MROH6 | SNV | Missense_Mutation | rs777114558 | c.572N>T | p.Ala191Val | p.A191V | A6NGR9 | protein_coding | deleterious(0.05) | possibly_damaging(0.528) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MROH6 | SNV | Missense_Mutation | novel | c.881G>A | p.Arg294Gln | p.R294Q | A6NGR9 | protein_coding | tolerated(0.17) | benign(0.005) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| MROH6 | SNV | Missense_Mutation | rs781182992 | c.187N>A | p.Ala63Thr | p.A63T | A6NGR9 | protein_coding | tolerated_low_confidence(0.5) | benign(0) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MROH6 | SNV | Missense_Mutation | rs747367163 | c.833G>A | p.Arg278His | p.R278H | A6NGR9 | protein_coding | tolerated(0.17) | benign(0) | TCGA-AA-3660-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MROH6 | SNV | Missense_Mutation | c.1718C>T | p.Ala573Val | p.A573V | A6NGR9 | protein_coding | tolerated(0.07) | benign(0.225) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| MROH6 | SNV | Missense_Mutation | c.1678N>A | p.Ala560Thr | p.A560T | A6NGR9 | protein_coding | tolerated(0.2) | benign(0.06) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MROH6 | SNV | Missense_Mutation | c.1847N>A | p.Arg616Gln | p.R616Q | A6NGR9 | protein_coding | tolerated(0.08) | possibly_damaging(0.587) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MROH6 | SNV | Missense_Mutation | c.1172N>A | p.Arg391Gln | p.R391Q | A6NGR9 | protein_coding | tolerated(0.44) | benign(0.011) | TCGA-EF-5830-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MROH6 | SNV | Missense_Mutation | novel | c.428N>A | p.Gly143Asp | p.G143D | A6NGR9 | protein_coding | deleterious(0.02) | benign(0.254) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |